If our findings can be extended to in vivo studies, it raises a possibility for a potential utility of LSD1 inhibitors in the treatment of a variety of forms of G6Pase-independent glycogen storage diseases and hepatocellular carcinoma. This evidence concerns the gene KDM1A and Glycogen storage disease due to glycogenin deficiency.